Hatteras Venture Partners

Hatteras Venture Partners

Signal active

Investment Firm

Overview

Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine.

Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to building successful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.

Highlights

Founded

2000

Industry

Financial Services

Employees

11-50

Investment

113

Lead Investment

40

Exits

25

Stages

Early Stage Venture, Late Stage Venture, Seed, Private Equity

Investor Type

Venture Capital

Location

United States, North America

Contact Information

Social

Profile Resume

Hatteras Venture Partners, established in 2000 and headquartered in United States, North America., specializes in Early Stage Venture, Late Stage Venture, Seed, Private Equity investments across Enterprise Software, Information Technology, Software, Computer, Financial Services, Venture Capital, SaaS, Health Care, Medical Device, Finance. The organization boasts a portfolio of 113 investments, with an average round size of $25.8M and 25 successful exits. Their recent investments include ArtusLabs, Southern Capitol Ventures, SpineAlign Medical, Intersouth Partners, Novartis Venture Fund. The highest investment round they participated in was $227.6B. Among their most notable exits are ArtusLabs and Southern Capitol Ventures. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.

Employees

imagePlace Clay B. Thorp

Clay B. Thorp

General Partner and Co-Founder

imagePlace Kenneth Lee

Kenneth Lee

General Partner

imagePlace Robert A. Ingram

Robert A. Ingram

General Partner

imagePlace Douglas Reed

Douglas Reed

General Partner

imagePlace Christy L. Shaffer

Christy L. Shaffer

General Partner

imagePlace Myla Lai-Goldman

Myla Lai-Goldman

Venture Partner

Investment portfolio

Hatteras Venture Partners has made 113 investments. Their most recent investment was on Jun 25, 2024, when Endogenex raised $88.0M.

Hatteras Venture Partners has made 28 diversity investments. Their most recent diversity investment was on Jun 07, 2022, when Code Biotherapeutics raised $75.0M.

investments

113

Diversity investments

28

Lead investments

40

Number of exits

25

Investments

113

Annouced DateOrganization NameIndustryMoney Raised
Jun 20, 2023
Veralox Therapeutics Veralox Therapeutics
Biotechnology24.0M
Apr 22, 2024
iVEAcare iVEAcare
Health Care27.5M
Apr 24, 2024--28.0M
Jun 25, 2024
Endogenex Endogenex
Health Care88.0M

Exits

25

Funding Timeline

Funding rounds

113

Investors

0

Funds

5

Funding Rounds

113

Hatteras Venture Partners has raised 113 rounds. Their latest funding was raised on Jun 25, 2024 from a Series C - Endogenex round.

Annouced DateTransaction NameNumber of InvestorsMoney RaisedLead Investor
Jun 20, 2023
Venture Round - Veralox Therapeutics Venture Round - Veralox Therapeutics
-24.0M-
Apr 22, 2024
Series A - iVEAcare Series A - iVEAcare
-27.5M-
Apr 24, 2024
Series C - AtaCor Medical Series C - AtaCor Medical
-28.0M-
Jun 25, 2024
Series C - Endogenex Series C - Endogenex
-88.0M-

Investors

0

There is no funding round available on this profile

Fund raised

2

Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.

Annouced DateFund NameMoney Raised
May 10, 2013
fund image OTPPLESS
1.0M
May 11, 2013
fund image OTPPLESS
1.0M

Invest in industries

Recent Activity

There is no recent news or activity for this profile.